Imuldosa®

Understanding Imuldosa®
Imuldosa® (ustekinumab-srlf) is an FDA-approved biosimilar to Stelara® (ustekinumab), indicated for the treatment of chronic inflammatory conditions including moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It targets interleukin-12 and interleukin-23 (IL-12/23), key cytokines involved in immune-mediated inflammation, helping to reduce immune system overactivity. Imuldosa® offers a biosimilar alternative to its reference product, with no clinically meaningful differences in safety, efficacy, or pharmacokinetics. It is administered via subcutaneous injection for all indications, with intravenous infusion used only for induction therapy in Crohn’s disease and ulcerative colitis.

How Imuldosa® Works:

• Targets IL-12 and IL-23, two cytokines that drive chronic inflammation in immune-mediated diseases
• Helps reduce inflammation, easing symptoms of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis
• Provides long-term symptom control with flexible dosing options: subcutaneous injection for maintenance, intravenous infusion for induction in select conditions

FDA Approval:
2024 – Imuldosa® gained FDA approval as a biosimilar to Stelara® for use in adults and pediatric patients (ages 6 and older) with plaque psoriasis and psoriatic arthritis, and in adults with Crohn’s disease and ulcerative colitis

For more information, please visit the Imuldosa® patient website. Speak with your healthcare provider to determine if Imuldosa® is the right treatment option for you.